Bladder Cancer Treatments

Find Bladder Cancer Treatments

Brand Name

Cysview

Generic Name
Hexaminolevulinate
View Brand Information
FDA approval date: May 01, 2018
Form: Kit

What is Cysview (Hexaminolevulinate)?

Cysview is indicated for use in the cystoscopic detection of carcinoma of the bladder, including carcinoma in situ , among patients suspected or known to have lesion on the basis of a prior cystoscopy, or in patients undergoing surveillance cystoscopy for carcinoma of the bladder. Cysview is used with the Karl Storz D-Light C Photodynamic Diagnostic system to perform Blue Light Cystoscopy as an adjunct to the white light cystoscopy. Cysview is an optical imaging agent indicated for use in the cystoscopic detection of carcinoma of the bladder, including carcinoma in situ , among patients suspected or known to have lesion on the basis of a prior cystoscopy, or in patients undergoing surveillance cystoscopy for carcinoma of the bladder. Cysview is used with the Karl Storz D-Light C Photodynamic Diagnostic system to perform Blue Light Cystoscopy as an adjunct to the white light cystoscopy. Important Limitations of Use: Not a replacement for random bladder biopsies or other procedures used in the detection of bladder cancer.

Approved To Treat

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances

Related Clinical Trials

Non-inferiority, Phase IV, Open-label, Randomized Controlled Trial of Vesical Imaging- Reporting and Data System (VI-RADS) Followed by Primary Photodynamic Trans-urethral Resection of Bladder Tumours (PDD-TURBT) Versus Conventional White-light TURBT Plus Repeated-TURBT (Re-TURBT) in Non-Muscle Invasive Bladder Cancers (NMIBCs) Candidate for Second Look and Resection

Background: In European Association of Urology (EAU) Guidelines, the vast majority of non-muscle-invasive bladder cancers (NMIBCs) undergo a primary transurethral resection of the bladder tumor (TURBT) followed by a repeat TURBT (Re-TURBT). The Re-TURBT is recommended due to the possibility of residual bladder cancer but is unnecessary in many cases by constituting overtreatment. Currently, no diagnostic stra...

Blue Light Cystoscopy With Cysview® Registry

Summary: Registry study to gather more information on the current use of Blue Light Cystoscopy with Cysview (BLCC) in urologists' practices.

Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection

Summary: Comparing white-light cystoscopy (WLC) and blue-light cystoscopy (BLC) in TURBT for high risk (HR) non-muscle invasive bladder cancer (NMIBC) patients is crucial to determine the most effective method for reducing residual disease burden and improving recurrence-free survival. Enhanced visualization with BLC may lead to more accurate resections, potentially decreasing recurrence rates and improvin...

Brand Information

Cysview (Hexaminolevulinate hydrochloride)
1INDICATIONS AND USAGE
CYSVIEW is indicated for the cystoscopic detection of carcinoma of the bladder, including carcinoma in situ (CIS), in adult patients:
  • With suspected or known lesion(s) based on a prior cystoscopy
  • Undergoing surveillance cystoscopy for bladder cancer
Limitations of Use
CYSVIEW is not a replacement for random bladder biopsies or other procedures used in the detection of bladder cancer
2DOSAGE FORMS AND STRENGTHS
For intravesical solution: 100 mg of hexaminolevulinate hydrochloride as a white to off-white or pale yellow freeze-dried powder for reconstitution with the supplied diluent.
3CONTRAINDICATIONS
CYSVIEW is contraindicated in patients with:
  • Porphyria
  • Known hypersensitivity to hexaminolevulinate or any derivative of aminolevulinic acid
4ADVERSE REACTIONS
The following clinically significant adverse reaction is discussed elsewhere in the Prescribing Information:
  • Anaphylaxis
4.1Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety of CYSVIEW was evaluated in 1,628 patients in seven clinical trials. Patients were aged 32 to 96 years with a median age of 70 years, 77% male, 88% White, 3% Black or African American, and 9% of unspecified racial group. All patients were evaluated after a single instillation of 100 mg of CYSVIEW, and 103 patients received a repeat administration of CYSVIEW
The most common adverse reaction was bladder spasm (reported in 2% of the patients) followed by dysuria, hematuria, and bladder pain.
4.2Postmarketing Experience
The following adverse reactions have been identified during post-approval use of CYSVIEW. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure:
Anaphylactic shock, hypersensitivity reactions, bladder pain, cystitis, and abnormal urinalysis.
5DESCRIPTION
CYSVIEW (hexaminolevulinate hydrochloride) for intravesical solution is an optical imaging agent.
The chemical name of hexaminolevulinate hydrochloride is hexyl 5-amino-4-oxopentanoate hydrochloride, and it has a molecular formula of C
Chemical Structure
CYSVIEW and DILUENT for CYSVIEW are supplied together as a kit:
  • CYSVIEW is a sterile, non-pyrogenic, freeze-dried, white to off-white or pale yellow powder provided in a clear glass vial. Each vial contains 100 mg hexaminolevulinate hydrochloride (equivalent to 85 mg hexaminolevulinate).
  • The DILUENT for CYSVIEW is a sterile, non-pyrogenic, clear, colorless solution (pH 6) free from visible particles provided in a 50 mL plastic prefilled syringe. Each mL contains 0.61 mg disodium hydrogen phosphate, 0.58 mg potassium dihydrogen phosphate, 7.02 mg sodium chloride, hydrochloric acid and sodium hydroxide for pH adjustment, and water for injection.
The reconstituted solution of CYSVIEW contains 2 mg/mL of hexaminolevulinate hydrochloride and is colorless to pale yellow. It is free from visible particles and has a pH between 5.7 and 6.2.
6CLINICAL STUDIES
The safety and effectiveness of CYSVIEW to detect bladder carcinoma during cystoscopic examination were studied in two prospective, open-label, controlled clinical trials: Study 1 and Study 2.
Study 1: Patients with Known or Suspected Bladder Cancer
A total of 779 patients with known or suspected bladder cancer were randomized to a control group of 384 patients or a study drug group of 395 patients. Patients in the study drug group received CYSVIEW by bladder instillation. After bladder evacuation of CYSVIEW, lesion mapping was performed using the KARL STORZ PDD system, initially in white light (WL) mode and then in blue light (BL) mode. Patients in the control group underwent lesion mapping using only WL cystoscopy and did not receive CYSVIEW. The average age of the randomized patients was 69 years (range 24 to 96). The study population was 78% male and 94% White. All patients included in the study had a history of previous cystoscopy.
The main diagnostic efficacy outcome was assessed within the study drug group. This assessment compared lesions detected during an initial cystoscopic examination to their centralized histologic findings (the standard of truth). Following the initial diagnostic cystoscopy, patients within both study groups who had histologically confirmed Ta and/or T1 lesions underwent follow-up WL cystoscopy at 3, 6 and 9 months; these histologic evaluations were based upon the site assessments at both the initial and follow-up cystoscopy.
Diagnostic efficacy assessed the number of patients within the study drug group who had at least one additional Ta or T1 bladder cancer detected only by BL; the proportion of these patients was compared to a proposed threshold proportion of 10%. Within the study drug group, 286 patients had at least one Ta and/or T1 lesion, including 47 patients who had at least one of the lesions detected only by BL (see
Some malignant lesions were detected only by WL or BL (see
Among the lesions detected only by BL, 23% were negative for any carcinoma-related pathology, including dysplasia. Among the lesions detected only by WL, 17% were negative for any carcinoma-related pathology, including dysplasia.
Study 2: Patients Undergoing Surveillance Cystoscopy
The study included 304 patients with a history of bladder cancer who were undergoing follow-up surveillance for tumor recurrence. The average patient age was 69 years with a range of 35 to 92 years. The study population was 80% male and 89% White.
For the initial surveillance examination, all 304 patients received CYSVIEW by bladder instillation, which was then evacuated. A surveillance cystoscopy was then performed, first using standard WL and subsequently using BL with the KARL STORZ D-Light C Photodynamic Diagnostic (PDD) System with the Flexible PDD Videoscope System. During this phase, suspected malignant lesions were counted and evaluated.
A total of 103 patients had suspected recurrence and then proceeded to a second examination in an operating room (OR). These patients received another CYSVIEW instillation, followed by WL and BL rigid cystoscopy for lesion mapping using the KARL STORZ D-Light C PDD System with the Rigid PDD Cystoscope System. All suspicious lesions were then biopsied and surgically removed by TURB.
Efficacy was assessed by determining the proportion of patients with a malignancy detected only with BL cystoscopy and not WL cystoscopy during the initial surveillance cystoscopic examination. The assessment was performed at patient-level, and compared malignancy detected during the surveillance cystoscopic examination to the centralized histologic findings (the standard of truth) obtained in the OR examination.
Table 3 shows patient-level detection of malignancy suspected in cystoscopic surveillance stage that was verified in the OR stage (n=103). Among the 103 patients, 63 patients had malignancy confirmed: 49 patients had malignancy detected by both WL and BL; 1 patient had malignancy detected by WL only; and 13 patients had malignancy detected by BL only [12.6% with 95% CI (7%, 21%), p<0.0001
Among 26 patients with confirmed CIS malignancy, 9 patients had CIS malignancy detected by BL only and 17 patients had CIS malignancy detected by both WL and BL.
In the same study, there were 315 lesions detected during the cystoscopy in the OR. Table 4 shows the detection of lesions by type of malignancy.
7HOW SUPPLIED/STORAGE AND HANDLING
How Supplied
CYSVIEW (hexaminolevulinate hydrochloride) for intravesical solution is supplied as a kit. It is available in the following two configurations:
  • CYSVIEW Kit with Vial Adapter (NDC 10511-3001-2): This kit contains:
  • One vial of CYSVIEW: 100 mg of hexaminolevulinate hydrochloride as a white to off-white or pale yellow freeze-dried powder in a 10 mL clear glass vial
  • One DILUENT for CYSVIEW: 50 mL as a clear, colorless solution in plastic prefilled syringe
  • One Luer Lock catheter adapter
  • One vial adapter (either West Vented Vial Adapter or West Mixject Dispensing Pin)
  • CYSVIEW Kit without Vial Adapter (NDC 10511-3001-3): This kit contains:
  • One vial of CYSVIEW: 100 mg of hexaminolevulinate hydrochloride as a white to off-white or pale yellow freeze-dried powder in a 10 mL clear glass vial
  • One DILUENT for CYSVIEW: 50 mL as a clear, colorless solution in plastic prefilled syringe
  • One Luer Lock catheter adapter
8PATIENT COUNSELING INFORMATION
Anaphylaxis
Inform patients that CYSVIEW may cause severe hypersensitivity reactions including anaphylactic shock. Instruct patients to seek immediate medical attention if they experience any symptoms of hypersensitivity reactions
Administration Instructions
Inform patients that CYSVIEW should be retained in the bladder for at least 1 hour from instillation of CYSVIEW to the start of the cystoscopic procedure. If the patient cannot hold CYSVIEW for 1 hour and needs to void and expel CYSVIEW from the bladder, they may void and should then inform a healthcare professional
9PRINCIPAL DISPLAY PANEL - Kit Carton
CYSVIEW for Intravesical Solution
100 mg/vial
NDC 10511-3001-2
ONE KIT
Sterile.
Rx ONLY
For Bladder Instillation Only after Reconstitution
Each KIT contains:
1 vial Cysview® (heaminolevulinate HCl) for Intravesical Solution 100 mg
1 DILUENT for Cysview® in prefilled syringe
1 Luer Lock catheter adapter
1 vial adapter
Store at 20°-25°C (68°-77°F); excursions permitted to 15°-30°C (59°-86°F) [see USP].
Dosage and Administration:
See insert for recommended dosage.
Reconstitute Cysview® (hexaminolevulinate HCl) for Intravesical Solution vial only with
PHOTOCURE
PRINCIPAL DISPLAY PANEL - Kit Carton